Day: April 19, 2023

ZUG, Switzerland, April 19, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host today its Capital Markets Day for investors and analysts in New York and virtually. The live event will be held in New York, US, with a webcast available for virtual attendees, from 10:30-12:30 EDT (15:30-17:30 BST / 16:30-18:30 CEST). Register for the event and webcast here. The event will feature a series of presentations from its executive team who will provide a financial update and look to the year ahead at near-term catalysts and the Company’s publication roadmap. The program follows the release of important competitor data, as presented at the recent American Academy of Dermatology (AAD) Annual Meeting, and will highlight...

MINNEAPOLIS, April 19, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs announces a poster presentation highlighting the results for ivospemin (SBP-101) as a polyamine metabolism modulator in ovarian cancer at the American Association for Cancer Research (AACR), taking place April 14-19, 2023. The work reflects the Company’s ongoing collaboration with Johns Hopkins University School of Medicine. “The treatment of C57Bl/6 mice injected with VDID8+ ovarian cancer with SBP-101 in combination with chemotherapy was observed to significantly prolong survival and decrease overall tumor burden,” said Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer...

New preclinical data from study presented at the American Association for Cancer Research 2023 Annual Meeting, 18 April 2023 REHOVOT, Israel, April 19, 2023 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment (TME) to overcome tumor immune evasion and drug resistance, today shared new results presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando. The results demonstrate the potential of NT219, the Company’s novel small molecule dual inhibitor of IRS1/2 and STAT3 escape mechanisms, to work synergistically with either anti-PD1 or anti-CTLA4 drugs to reprogram the immune profile in the TME...

LONGBOAT KEY, Fla., April 19, 2023 (GLOBE NEWSWIRE) — Rumble Inc. (NASDAQ: RUM), the video-sharing platform, today announced that it will release financial results for the fiscal quarter ended March 31, 2023 after the close of markets on Monday, May 15, 2023. The company will host a conference call on the same day at 5:00 p.m. Eastern Time. Access to the live webcast and replay of the conference call, along with related earnings release materials, will be available here and on Rumble’s Investor Relations website at investors.rumble.com. About Rumble Rumble is a high-growth neutral video platform that is creating the rails and independent infrastructure designed to be immune to cancel culture. Rumble’s mission is to restore the Internet to its roots by making it free and open once again. For more information, visit corp.rumble.com. For...

NORTH BETHESDA, Md., April 19, 2023 (GLOBE NEWSWIRE) — Xometry, Inc. (NASDAQ: XMTR), the global online marketplace connecting enterprise buyers with suppliers of manufacturing services, today announced it will report its first quarter 2023 financial results before the market open on May 10, 2023. Xometry will host its conference call and webcast to discuss the results at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) on the same day. In addition to its press release announcing its first quarter 2023 financial results, Xometry will also release an earnings presentation, which will be available on its investor website at investors.xometry.com.   Xometry, Inc. First Quarter 2023 Earnings Presentation and Conference CallWednesday, May 10, 2023 8:30 a.m. Eastern / 5:30 a.m. Pacific To register please use the following link:https://register.vevent.com/register/BIb776f13895ac48c283ebd1dd5079490b You...

Data presented were crucial to initiating its ongoing Phase 1 clinical trial with Decoy 20 in solid tumors NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces data presented in a poster at the American Association for Cancer Research (AACR) annual scientific conference on the Company’s Decoy anti-tumor platform. The poster, titled, “A systemically administered killed bacteria-based multiple immune receptor agonist for pulsed anti-tumor immunotherapy,” authored by Michael J. Newman, Ph.D., the Company’s Founder and Chief Scientific Officer, was presented Tuesday, April 18, 2023. Highlights included:Decoy10 (a previous generation from the platform)...

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX) will be presenting in vitro results characterizing the role of sigma-2 (σ-2) receptors and effect of CT1812 in cell-based models of dry age-related macular degeneration (AMD). CT1812 is an experimental orally delivered, small molecule drug candidate that binds to σ-2 receptors, which have been shown to regulate key cellular processes involved in age-related degenerative diseases. In these in vitro studies, cultures of retinal pigment epithelial (RPE) cells derived from induced pluripotent stem cells (iPSC) as well as cultures of ARPE-19 cells, a cell line of naturally occurring RPEs, were subjected to conditions that lead to cellular dysfunction in dry AMD. Biological pathways impacted by disease-relevant stressors in RPE cells were identified,...